復星醫藥(02196.HK)與BioNTech擬於上海組合營生產新冠疫苗 股份早段升兩成
復星醫藥(02196.HK)公布,與BioNTech訂立一份條款書,為新冠疫苗產品的本地化生產及商業化而擬設立一家合資公司,雙方將分別持股50%,為期15年,註冊地為上海。
根據該條款書,復星醫藥產業同意以現金及/或有形、無形資產(包括廠房及生產設施等)向合資公司作價出資總額不超過1億美元,而BioNTech以其相關生產技術和專有技術許可等無形資產作價出資總額不超過1億美元。
復星醫藥產業應提供具備年產能可達10億劑新冠疫苗產品的生產設施,並作為出資的一部分注入合資公司。BioNTech應當負責辦理有關技術轉移(通過訂立技術許可協議)事宜及提供相關技術支持,且應確保有充足的適當人員。BioNTech就相關技術轉移及支持所產生的合理開支應由合資公司承擔。
另外,合資公司應聘請復星醫藥產業之聯屬公司作為合同銷售組織以提供合資公司的新冠疫苗產品在中國境內的推廣及銷售服務。合資公司應按照條款書約定向合同銷售組織支付服務費。
受消息刺激,復星醫藥股份最新報60.5元,升20.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.